Francisco Pasquel, MD, MPH Credit: Emory University

Use of the Omnipod 5 automated insulin delivery (AID) system decreased median HbA1c from 8.2% to 7.4% in 13 weeks among users with type 2 diabetes, according to results of the SECURE-T2D trial.

Billed as the largest, longest, and most racially diverse study of AID in people with type 2 diabetes to date, results of the SECURE-T2D trial demonstrate provided substantial benefit, including a nearly 5-hour increase in time in range per day, with results of AID use similar across subgroups defined by race/ethnicity, GLP-1 RA use, prior insulin regimen, and pre-study insulin meal dosing method.1,2

Our findings demonstrate substantial improvements in blood glucose outcomes and overall quality of life, highlighting the potential for this innovative technology to transform type 2 diabetes management with automated insulin delivery, said chair of the study Francisco Pasquel, MD, MPH, associate professor of Medicine of Emory University.2 As the largest study of AID therapy in people with type 2 diabetes, we look forward to these results supporting the FDA clearance of Omnipod 5 as a safe and effective therapy for this patient population.

With the receipt of FDA clearance for type 1 diabetes in January 2022, the Omnipod 5 became the first tubeless AID system with smartphone control. As the benefits of diabetes technology has continued to emerge in recent years, an interest in their utility among people with type 2 diabetes has become evident. At the 2024 International Conference on Advanced Technologies & Treatments for Diabetes, Insulet presented data from an 8-week feasibility study among adults with type 2 diabetes confirming the potential of the Omnipod 5 among this patient population.3,4

In SECURE-T2D, which was presented at the 84th American Diabetes Association Scientific Sessions, investigators enrolled 305 individuals from 21 sites across the US. For inclusion, patients were required to be 18 to 75 years of age, have type 2 diabetes, have been on their current insulin regimen for 3 or more months, and have no previous AID use. Investigators pointed out HbA1c requirements required patients to have an HbA1c less than 12% among basal/bolus or pre-mix insulin users and 7% or more and less than 12% among basal-only users.1

The study cohort had a mean age of 57 (SD, 11) years and 57% were female. The median duration of diabetes was 17 years, the mean HbA1c at screening was 8.2% (SD, 1.4), 62% were currently using CGM, and 25% had never used CGM. Regarding race and ethnicity, 50% of patients were non-Hispanic White, 24% were non-Hispanic Black, 22% were Hispanic or Latino, and 2% were Asian or Pacific Islander.1

Per trial design, participants underwent a 14-day period of standard therapy to collect baseline data, which was followed by a 13-week period where all patients received the Omnipod 5 AID system with the Dexcom G6 continuous glucose monitoring system.1

At the end of the 13 weeks, the mean HbA1c among the cohort decreased from 8.2% (SD, 1.3) at baseline to 7.4% (SD, 0.9) (treatment effect= -0.8%; 95% CI, -1.0 to -0.7; P <.001). When assessing secondary glycemic metrics, results indicated use was associated with a 20% increase in time in range of 70 to 180 mg/dL (4.8 hours per day) and a 20% decrease in time above 180 mg/dL (4.8 hours per day) (P <.001). Investigators pointed out these improvements in time in range were primarily driven by a significant reduction in hyperglycemia with no increase in hypoglycemia.1

When assessing secondary endpoints in a pre-specified hierarchical order, significance was achieved for the first 11 endpoints, including mean glucose, time in range of 70 to 180 mg/dL, time in range of 70 to 140 mg/dL, time at or above 300 mg/dL, time above 250 mg/dL, time above 180 mg/dL, time below 70 mg/dL, time below 54 mg/dL, diabetes distress, percentage with high distress scores, and sleep quality. After the 13-week period with Omnipod 5, 90% of participants indicated they would recommend Omnipod 5 to a friend and 78% of participants expressed interest in continuing use of Omnipod 5 following study conclusion.1

These data demonstrate that simple, easy-to-use AID technology, such as Omnipod 5, can be adopted by a broad population of people with type 2 diabetes and improve their lives, said Trang Ly, MBBS, PhD, senior vice president and medical director at Insulet Corporation.2 A major strength of this study is the diversity of the enrolled population in terms of varying education level, income, ethnicity, and race. These results could have a particularly striking impact among Black and Hispanic people, who experience a higher prevalence of type 2 diabetes and increased mortality rates.

References:

Read more:
Omnipod 5 AID System Proves Benefit for Adults with Type 2 Diabetes - MD Magazine

South Africas public health care system has run out of the human insulin pens that it provides to people with diabetes, as the pharmaceutical industry shifts production priorities to blockbuster weight-loss drugs that use a similar device for delivery.

Novo Nordisk, the company that has supplied South Africa with human insulin in pens for a decade, opted not to renew its contract, which expired last month. No other company has bid on the contract to supply 14 million pens for the next three years, at about $2 per pen.

Current manufacturing capacity limitations mean that patients in some countries, including South Africa, may have limited access to our human insulins in pens, said Ambre James-Brown, a spokeswoman for Novo Nordisk. The company did not reply to questions about which other countries are affected.

Novo Nordisks drugs Ozempic and Wegovy, which are widely prescribed in the U.S. for weight loss, are sold in single-use pens produced by many of the same contracted manufacturers who make the multidose insulin pens. A months supply of Ozempic in the United States costs about $1,000, far more than insulin.

Novo Nordisk dominates the global market for insulin in pens and has supplied South Africa since 2014. Eli Lilly, the other major producer, has indicated in recent months that it is struggling to keep up with the significant demand for its weight-loss drug Zepbound.

This is because of the global demand for Ozempic and these drugs, said Khadija Jamaloodien, the director of sector-wide procurement for South Africas health service. Theyre shifting the focus on the more profitable line.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit andlog intoyour Times account, orsubscribefor all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?Log in.

Want all of The Times?Subscribe.

Read more:
South Africa Runs Out of Insulin Pens as Global Supply Shifts to Weight-Loss Drugs - The New York Times

ORLANDO, Fla., June 22, 2024 /PRNewswire/ -- Today, the American Diabetes Association (ADA) announced the winners of its Innovation Challenge competition. Innovators showcased novel ideas for diabetes care before a panel of potentialfunders and an audience of professionals in the field, with the goal of furthering transformative solutions for people living with diabetes, their families, and caregivers. Five finalists pitched ideas from the main stage at the ADA's 84th Scientific Sessions and three winners were chosen Diatech Diabetes, Spotlight Communications, and Symbio Cell Tech.

The competition comes amidst a diabetes epidemic affecting over 38 million Americans. Increased efforts to bend the curve of diabetes, coupled with advancements in technology and scientific understanding have created a growing market for diabetes startups.

"The potentially game-changing ideas presented by these innovators bring the ADA's vision of a life free of diabetes and all its burdens closer to reality. We're proud to support emerging advancements in diabetes research and care," said Robert Gabbay, chief scientific and medical officer of the ADA. "Our congratulations to the winners, with appreciation for their hard work and excitement for what's to come."

This year's winners and finalists included:

Winner: Diatech Diabetes A software platform to improve infusion failure detection in insulin pump and automated insulin deliver (AID) systems. The mobile app integrates with insulin pumps allowing people with diabetes to monitor their infusions and avoid hyperglycemia.

Winner: Spotlight Communications A clinical tool to address patient-identified priority concerns and immediately map resources to meet unmet physical, mental and social wellbeing needs.

Winner: Symbio Cell Tech A biotherapy for patients with type 1 diabetes that does not require encapsulation devices or antirejection drugs.

Finalist: Spect A smartphone-enabled telemedicine platform for eye screening that trains medical assistants and returns a diagnostic report in minutes.

Finalist: Valendo Health Delivery of a program to address the shortage of endocrinologists, beginning with increasing clinical capacity and enhancing patient care by delivering telehealth and remote patient monitoring services.

The application period for next year's Innovation Challenge will open in January 2025.

About the American Diabetes Association's Scientific SessionsThe ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions.

About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociacin Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).

Media Contact: Amy Robinson [emailprotected]

SOURCE American Diabetes Association

Continued here:
The American Diabetes Association Names Winners of Diabetes Innovation Challenge - PR Newswire

Chapters

00:00 - Intro

00:40 - Abbott OTC CGM

06:20 - Diabetes Technology Pipeline

10:45 - JDRF Rebrands as Breakthrough T1D

15:15 -US FDA Clearance of CamAPS FX

In this episode ofDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives,hostsDiana Isaacs, PharmD, and Natalie Bellini, DNP, provide a June 2024 update focusing on a trio of topics across the spectrum of diabetes management. In the episode, hosts discuss the US Food and Drug Administration (FDA) clearance of 2 new over-the-counter (OTC) continuous glucose monitoring (CGM) systems from Abbott, the renaming of JDRF to Breakthrough T1D, and the FDA clearance of the CamAPS FX for people with type 1 diabetes.

After spotlighting Dexcoms Stelo in a previous episode, hosts started off this episode by discussing Abbotts announcement of US Food and Drug Administration clearance for a pair of new OTC CGM devices: the Lingo and the Libre Rio.1

Billed by Abbott as a consumer biowearable, the Lingo is designed for use by consumers 18 years and older looking to improve their overall health by offering them the ability to track glucose and provide personalized insights as well as customized coaching. The Lingo will feature a biosensor designed to be worn on the upper arm with a 14-day wear period. Data obtained by the sensor will be continuously streamed to a smartphone application for the user.1

Unlike the Lingo, the Libre Rio is billed by Abbott as the companys first OTC system for those with type 2 diabetes who do not use insulin and manage their diabetes with lifestyle modifications. The system boasts a measurement range of 40 to 400 mg/dL.1

On June 04, 2024, the JDRF announced it would be changing its name and will now be called Breakthrough T1D. Announced in a simulcast during the organizations annual Government Day Conference, the new name is a reflection of the medical communitys recognition that type 1 diabetes can develop at any age, regardless of family history.2

As an adult and scientist living with type 1 diabetes, I believe our new name, Breakthrough T1D, will help to deepen engagement and support across the entire community as we drive toward curing type 1 diabetes, said Aaron J. Kowalski, PhD, chief executive officer of Breakthrough T1D.2

To complete the episode, the hosts celebrate a long-awaited announcement for those up to date on developments in diabetes technology: the US FDA approval of CamAPS FX.3,4

A prescription-only mobile application developed by CamDiab Ltd, CamAPS FX is designed for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in people 2 years of age or older. However, much of the excitement surrounding the algorithm revolves around it being the first of its kind for use in pregnant patients who may have complications with type 1 diabetes.3,4

Compatible with other interoperable devices that meet pre-specified acceptance criteria, the application works with an integrated continuous glucose monitor to control a compatible insulin pump. At the time of clearance by the US FDA, the CamAPS FX closed-loop algorithm had already received clearance for a similar indication in Europe and been used by more than 27,000 people in 15 countries.3,4

References:

More:
Diabetes Dialogue: June 2024 Updates in Diabetes Tech and Type 1 Diabetes - MD Magazine

The Mobi miniature, durable automated insulin patch pump worn on a hikers leg. [Image courtesy of Tandem Diabetes Care] Tandem Diabetes Care (Nasdaq:TNDM) today announced real-world insights highlighting user satisfaction with its Mobi automated insulin pump.

San Diego-basedTandem launched Mobi, the worlds smallest, durable automated insulin delivery (AID) system in the U.S. this year. Itreceived FDA clearance for people with diabetes ages six and up in July 2023. The system pairs with both the Dexcom G6 and G7 CGMs, offering multiple options to patients. Tandem also plans to integrate Mobi (and its t:slim X2 pump) with the Abbott FreeStyle Libre 3 in the future.

Tandem shared a survey on user satisfaction and wearability, finding that 86% of patients reported that they were satisfied or very satisfied with Mobi regardless of prior therapy and agreed that Mobi helps improve their quality of life. The company presented its data at the American Diabetes Association Scientific Sessions in Orlando, Florida.

These real-world user insights provide evidence that we are furthering our mission to improve the lives of people with diabetes by demonstrating that Tandem Mobi not only meets, but exceeds user expectations, said Dr. Jordan Pinsker, chief medical officer at Tandem Diabetes Care. We are proud to share these results at ADA and will continue to innovate to provide the diabetes community with choice and improved quality of life.

In a six-week limited launch survey, the company heard from early users who previously used multiple daily injections (MDI), other insulin pumps (tubed and tubeless) or previous tandem pumps. They exhibited high satisfaction with the wearability features of Mobi combined with the Control-IQ algorithm.

Mobis size enables users to wear it almost anywhere with greater discretion, comfort and flexibility. Control-IQ technology, meanwhile, predicts and helps prevent highs and lows.

For prior pump users, 78% said Mobi reduces diabetes management burden and 88% say its easy to use, while 80% said it delivers more freedom in their lives.

Other data shared at ADA included Mobi users and highlighted improved time in range with no increase in time spent below range. Younger users highlighted form factor, portability, discreteness and wearability as paramount to satisfaction and ongoing use.

Tandem highlighted a number of features contributing to these satisfaction drivers, including a 30-unit minimum fill to reduce insulin waste for those with low insulin requirements. Mobis physical on-pump quick bolus button enables simple, discreet bolusing with programming in grams or unit increments.

On-body wear features a lightweight adhesive sleeve and five-inch tubing, while users can control Mobi from their personal iPhone.

See the rest here:
Tandem reports improved quality of life with Mobi AID system - Drug Delivery Business News

An analysis of the SURMOUNT 1 and 2 trials presented at the 84th American Diabetes Association Scientific Sessions offers further insight into the differences in weight loss observed among people with and without type 2 diabetes achieved with use of tirzepatide.

Results of the study, which leveraged propensity score matching and mixed models for repeated measures (MMRM) analysis to compare the effect of Eli Lilly and Companys dual GIP/GLP-1 receptor agonist in those with overweight or obesity based on diabetes status, suggest the differences in weight reductions observed persisted after matching key baseline characteristics, which investigators purport indicates other contributing factors drive these differences.

The current study was led by Rodolfo Galindo, MD, of Emory University, to better understand potential drivers of the difference in effects seen with tirzepatide on body weight reductions in people with overweight or obesity with or without type 2 diabetes. With this in mind, investigators designed their study to use propensity score matched cohorts, with matching based on age, gender, weight, BMI, antidepressant use or depression, and obesity-related comorbidities, in MMRM analysis to compare the percent of weight reduction achieved at week 72 between those with and without type 2 diabetes form within SURMOUNT-1 and SURMOUNT-2.

Investigators pointed out initial analysis of the cohorts revealed those in SURMOUNT-2 were older, had a greater proportion of more males, lower weight, greater HbA1c, and greater comorbidity burden compared to their counterparts in SURMOUNT-1.

Results of the ADA 2024 study indicate the differences in weight reduction observed at week 72 remained even after propensity score matching, with those in the SURMOUNT-1 cohort achieving greater levels of body weight reduction than their counterparts in SURMOUNT-2 with type 2 diabetes.

For more on the study, check out our interview with study investigator W. Timothy Garvey, MD, director of the Diabetes Research Center at the University of Alabama - Birmingham.

Relevant disclosures for Dr. Garvey include Boehringer-Ingelheim, Novo Nordisk, Eli Lilly and Company, Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Fractyl Health, Inc., Inogen, Epitomee, Pfizer Inc., and Neurovalens.

References:

See the original post:
Timothy Garvey, MD: Drivers of Differences in Weight Loss with Incretins Based on Diabetes Status - MD Magazine

Findings Reveal Efficacy of Novel Inhaler to Improve Glycemic Control for Patients with Type 1 Diabetes

ORLANDO, Fla., June 22, 2024 /PRNewswire/ --Today, findings from INHALE-3, a pivotal trial examining the use of inhaled insulin in adults with type 1 diabetes (T1D), were announced, highlighting the potential of an alternative insulin solution to enhance diabetes management. The results were presented as a symposium at the 84th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, FL.

Type 1 diabetes affects 11.6% of the American population and millions of individuals globally, requiring ongoing insulin therapy to manage blood glucose levels. Traditional insulin delivery methods include multiple daily injections or automated insulin delivery systems. However, for some patients, there is a need for new solutions to improve convenience, ease of use, and effective glycemic management.

INHALE-3, a randomized trial, compared the efficacy of an inhaled insulin regimen (Afrezza) plus degludec insulin (Tresiba) against usual care over 17 weeks at 19 centers in the U.S. The trial included 123 adults with type 1 diabetes divided into two groups: one receiving inhaled insulin (Afrezza) plus degludec insulin, and the other continuing their usual care, which included automated insulin delivery systems in about half or multiple daily injections. The study's primary endpoint was a change in HbA1c levels, a critical marker of long-term blood glucose control. Secondary endpoints included changes in time-in-range and hypoglycemia measured with continuous glucose monitoring and patient-reported outcomes on insulin delivery satisfaction.

More participants using the inhaled insulin regimen experienced significant improvements in HbA1c levels compared to those on usual care. Notably, 21% of those on inhaled insulin had an HbA1c improvement of greater than 0.5%, while this was seen in only 5% of those with standard care. Furthermore, among participants who had an HbA1c level greater than or equal to 7% at the start of the study, 21% of those on inhaled insulin achieved the HbA1c goal of less than 7% while no participants receiving standard care achieved this HbA1c goal. Nineteen percent of participants who switched from using an automated insulin delivery system to using inhaled insulin plus degludec achieved an HbA1c improvement greater than 0.5%. In contrast to these positive findings, the study found that the insulin regimen with inhaled insulin and degludec was not for everyone: 26% of the patients in the inhaled insulin group had a worsening of HbA1c greater than 0.5% compared with 3% with standard care. Importantly, over half of the study participants wished to continue the inhaled insulin after the study completion.

"The INHALE-3 study's findings will impact diabetes management by providing healthcare providers and patients with an alternative insulin delivery method," said Irl B. Hirsch, MD, University of Washington, and lead author of the study. "These results will assist in better informing clinical decisions and tailoring treatment plans to individual patient needs, potentially improving adherence, patient satisfaction, and overall outcomes."

Building on the promising results of INHALE-3, further research will focus on the impact of inhaled insulin on a broader patient population, including pediatrics and pregnancy. These studies aim to reinforce the role of inhaled insulin in comprehensive diabetes care.

Research presentation details:

Dr. Hirsch will present the findings at the following symposium:

About the ADA's Scientific Sessions

The ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions.

About the American Diabetes Association

The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us atdiabetes.orgor call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociacin Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).

Contact: Amy Robinson [emailprotected]

SOURCE American Diabetes Association

Read more:
Study Shows Promising Results for Inhaled Insulin as Treatment for Type 1 Diabetes - PR Newswire

Findings Highlight the Impact of Insurance Barriers on Managed Diabetes Care for Diverse Populations Living with Type 1 Diabetes

ORLANDO, Fla., June 21, 2024 /PRNewswire/ -- Results from a new study show the impact and importance of continuous glucose monitoring (CGM) that young individuals with diabetes face today. The findings were presented as a Late-Breaking Poster at the 84th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, FL.

Health disparities is a growing concern that significantly impacts diabetes. In nearly all states, those who identify as Black and Native American are more likely than those who identify as Asian American, Hispanic/Latino, and White to die from complications of diabetes. Over half of Hispanic/Latino adults are predicted to develop type 2 diabetes during their lives.

"People with type 1 diabetes are at a heightened risk for health complications as they age. They all deserve access to care and treatment, no matter their no matter their race, income, ZIP Code, age, education, or gender," said Robert Gabbay, MD, PhD, ADA chief scientific and medical officer. "The findings from the studies presented at this year's Scientific Sessions are encouraging, as we strive to develop innovative, evidence-based solutions to support a diverse population of people living with diabetes and maintain their care."

The use of CGM reduces HbA1c and is recommended by the American Diabetes Association within 12 months of a type 1 diabetes diagnosis. This study examines the impact of insurance, race, and ethnicity on the timing of CGM initiation in children with type 1 diabetes and compares glycemic control between those who start CGM within six months of diagnosis versus later.

Children up to age 21 diagnosed with T1D at UCSF Benioff Children's Hospitals between February 2015 and September 2021 (n = 270) were grouped by CGM initiation time. Insurance, race, and ethnicity were analyzed using one-way ANOVA (Kruskal-Wallis H-test) to determine if samples originated from the same distribution. T-tests and Wilcoxon tests compared early and late CGM initiation. Data normality was assessed with QQ plots and density plots.

Results showed that on average publicly insured children started CGM within six months, while privately insured children started CGM within two months. Similar delays were observed for children from historically marginalized racial or ethnic groups compared to White, non-Latinx children. The average HbA1c was 7.5% for children who started CGM within six months of diagnosis, compared to 8.4% for those who started later. Barriers to CGM initiation contribute to less optimal glycemic control for publicly insured and racially and ethnically minoritized children, increasing the risk of complications. Addressing these disparities could improve early blood sugar control and health outcomes.

"Our results highlight the marked difference in HbA1c in children that receive CGM early on," said Mette K Borbjerg, lead author from the Steno Diabetes Center North Denmark and Division of Pediatric Endocrinology, University of California San Francisco. Dr. Borbjerg's co-authors include Annika Kvist (Steno Diabetes Center North Denmark), Kala Mehta (Department of Epidemiology, University of California San Francisco), Niels Ejskjaer (Steno Diabetes Center North Denmark and Department of Internal Medicine and Endocrinology, Aalborg University Hospital), and senior author Jenise Wong (Division of Pediatric Endocrinology, University of California San Francisco)."Ensuring timely CGM access for all children is essential to reduce complication risks.This highlights the need for practices and policies to address barriers to CGM initiation and healthcare access."

Future research should focus on understanding the specific barriers preventing timely CGM initiation. A follow-up study assessing long-term health care outcomes in children with early vs late CGM initiation could provide evidence to advocate for policy changes.

Research presentation details:

Dr. Borbjerg will present the findings at the following Late- Breaking poster session:

About the ADA's Scientific SessionsThe ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions.

About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us atdiabetes.orgor call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociacin Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).

CONTACT: Amy Robinson [emailprotected]

SOURCE American Diabetes Association

See the original post:
New Research Indicates the Need for Diabetes Continuous Glucose Monitoring to Address Health Disparities - PR Newswire

People with diabetes who are hospitalized often face challenges if they use continuous glucose monitoring. Hospital staff may not be familiar with different CGM devices, or may not know how to use them for insulin dosing. And while CGM use in a hospital setting isn't currently approved by the FDA, new research shows that patients benefit from using their own devices, which could be influential in moving away from finger sticks as the standard.

Researchers from Stanford Health Care developed a hospital-wide plan for CGM use for insulin dosing, in a study in 2022 to 2023. The results showed CGM use was effective for patients, with 87.7% success meeting the accuracy criteria for insulin dosing. About 1,500 CGM readings from 135 patients using their personal CGM were validated using a finger stick test. Study results were presented at the 2024 American Diabetes Association Scientific Sessions in Orlando.

Dr. Susan Seav, an endocrinology fellow at Stanford Medicine, and the other researchers in the study developed a chart that nurses could use for making dosing decisions for the majority of hospital patients they treated, who were using Dexcom and Libre sensors.

"We think that the creation and implementation of an inpatient CGM protocol with real-time device accuracy monitoring is feasible and allows for insulin dosing based on personal CGM data," Seav said. "By sharing our experience and our data, we really hope to establish CGM use as part of the standard of care when appropriate. And we also want to encourage and empower other institutions to adopt similar protocols."

The study also found that a large majority of nurses 80% preferred CGM use to finger sticks. And most nurses found inpatient CGM use effective, easy to use, and efficient.

"The ADA has said people should, if at all possible, be allowed to continue to use their CGM right in the hospital," said Dr. Nicholas Argento, diabetes technology director at Maryland Endocrine and Diabetes, who attended a presentation of the study but was not involved in it. "But hospitals need to have a protocol in order to allow this. In this study, the accuracy was excellent."

More:
CGM Use in Hospitals Helps Patients and Nurses - diaTribe Foundation